IMVT

Immunovant Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↓ 0/10
  • Value↑ 5/10
Immunovant sales and earnings growth
IMVT Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -2.29%
  • FCF Y/Y↓ -29.92%
Immunovant gross and profit margin trends
IMVT Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↑ 4565.91%
Immunovant net debt vs free cash flow
IMVT Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Immunovant stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗